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ÖZET:
Metamfetamine bağlı psikozda aripiprazol: 
Bir açık çalışma 
Amaç: Bu çalışmada metamfetamin bağımlılığı olan 
hastalardaki psikozun tedavisinde aripiprazol’ün tera-
pötik etkisini ve tolerabilitesini değerlendirmek amaç-
lanmıştır.
Yöntem: Bu prospektif tek kollu açık çalışma Malaya 
Üniversitesi Tıp Merkezi’nde [University  Malaya Medical 
Centre (UMMC)] yürütülmüştür. Çalışmaya DSM-IV’e 
göre metamfetamin bağımlılığı ile birlikte akut psiko-
tik semptomları bulunan hiç tedavi almamış hastalar 
alındı. Çalışmaya alınan hastalara başlangıçta 5-10 mg, 
sonraki 2-14 günde esnek dozda (5-15 mg/gün) aripip-
razol verildi. 
Bulgular: Çalışmaya katılan 49 hastadan 41’ i (%83.7) 
çalışmayı tamamladı. Başlangıç PANSS toplam puanı 
ortalaması 79.2±13.7 ve CGI-S puanı ortalaması 4.3±0.5 
idi. Çalışma sonunda PANNS-toplam ve CGI-S puanların-
da istatistiksel olarak anlamlı ölçüde azalma gözlendi. 
Başlangıca göre 14’üncü günde PANSS puanında orta-
lama 27.6±21.4 puan [p<0.05,  95%  CI  (-34.8,  -20.4)] ve 
CGI-S puanında ortalama 2.0±1.2  puan [p<0.05,  95% 
CI  (-2.4,  -1.6)] saptandı. Çalışma süresince aripiprazol 
genel olarak iyi tolere edildi. On (%20.4) hastada yan 
etki rapor edildi. Hareket ile ilişkili yan etkiler bakımın-
dan istatistiksel olarak anlamlı bir farklılık saptanmadı. 
Sonuç: Bu çalışmada metamfetamin kullanımıyla ilişkili 
psikotik semptomların aripiprazol tedavisiyle düzeldi-
ği saptandı. Aripiprazol hafif-orta düzeydeki yan etki 
profili ile genel olarak iyi tolere edildi. Bu bulgular 
ışığında aripiprazol metamfetamin ile ilişkili psikozun 
tedavisinde etkili ve güvenli bir tedavi seçeneği olarak 
düşünülebilir. 
Anahtar sözcükler: Metamfetamin bağımlılığı, psikoz, 
aripiprazol, açık çalışma, güvenlik, etkililik 
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ABS TRACT:
An open-label study of aripiprazole for 
methamphetamine induced psychosis 
Objective: This study aimed to explore the therapeutic 
effects and tolerability of aripiprazole in the treatment 
of psychosis among methamphetamine dependent 
patients. 
Methods: This was an open label single arm 
prospective study conducted at the University Malaya 
Medical Centre (UMMC). The study subjects included 
treatment naive patients with a current diagnosis of 
methamphetamine dependence with co-occurring 
acute psychotic symptoms based on the Diagnostic 
and Statistical Manual of Mental Disorders-IV (DSM-
IV). Eligible patients were treated with an initial dose 
of 5-10 mg aripiprazole followed by flexible doses 
(5-15mg/day) from day 2 to 14.
Results: Out of 49 patients enrolled, 41 patients 
(83.7%) completed the study. At baseline the mean 
PANSS total score was 79.2±13.7 and the mean CGI-S 
score was 4.3±0.5. There was a statistically significant 
decline in the mean PANSS-total and CGI-S scores 
over the course of the study. The mean reduction 
was 27.6±21.4 point (p<0.05, 95% CI (-34.8, -20.4)) 
from baseline on day 14 for total PANSS score and 
2.0±1.2 point (p<0.05, 95% CI (-2.4, -1.6) for CGI-S. 
Aripiprazole was generally well tolerated during the 
study. Adverse events were reported in 10 (20.4%) 
patients. No statistically significant changes were noted 
with respect to movement-related adverse events. 
Conclusions: This study found that aripiprazole 
improved the psychotic symptoms associated with 
methamphetamine use. It was generally well tolerated 
with mild to moderate adverse events. Based on these 
results aripiprazole might be an effective and safe 
option for the treatment of methamphetamine induced 
psychosis.
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 INTRODUCTION
 Methamphetamine (MA) is a psycho-stimulant drug 
with addictive and long lasting stimulant effects. Because 
of its wide availability and lower cost, methamphetamine 
has become one of the most commonly consumed illicit 
substances, not only locally in Malaysia, but globally as 
well (1). Acutely, methamphetamine can trigger psychotic 
symptoms in individuals with no past history of psychosis 
(2). Accumulated evidence has indicated that chronic use 
of methamphetamine gradually leads to the development 
of a psychotic state resembling paranoid schizophrenia 
(3). It has been reported that methamphetamine dependent 
users were three times more likely to experience psychotic 
symptoms than non-regular methamphetamine users (4).
 Although methamphetamine induced psychiatric 
disorders are typically self-limiting, treatment may be 
required in emergency situations, as well as to prevent 
recurrence. Recurrence of psychotic symptoms can occur 
due to the continued use of methamphetamine or other 
drugs, and also due to psychosocial stressors (5, 6). In 
some cases psychosis may persist and around 5 -15% of 
methamphetamine users fail to recover completely (7).
 To date, there is little empirical evidence on 
pharmacological treatment options for methamphetamine 
induced psychosis. Most published data consists of case 
reports and small open label studies (8). There is currently 
no approved medication by the Food and Drug 
Administration (FDA) or the Malaysian Drug Authority 
for the treatment of methamphetamine induced psychosis.
 An early study showed that intramuscular haloperidol 
administration significantly reduced the symptoms of 
methamphetamine induced excitement and paranoid 
ideation within an hour (9). Droperidol was also shown to 
sedate agitated methamphetamine users significantly 
faster than lorazepam after intravenous administration 
(10). Case studies with the newer atypical antipsychotics 
such as olanzapine (11), risperidone (12) and quetiapine 
(13) have also revealed possible benefits.
 Aripiprazole is an atypical antipsychotic medication 
indicated for the treatment of schizophrenia and acute 
manic episodes associated with bipolar 1 disorder. Unlike 
other atypical antipsychotics (e.g. olanzapine, quetiapine, 
risperidone) that act as antagonists at D2 dopamine 
receptors (14,15), aripiprazole appears to mediate its 
antipsychotic effects primarily by partial agonism at D2 
receptors (16,17,18). This partial agonist effect stabilizes 
dopamine receptors while allowing a modulation of 
function, rather than blocking them exclusively. Therefore, 
partial agonists are also known as dopamine system 
stabilizers, which constitute a new class of antipsychotic 
agents without leading to apparent motor side effects (19). 
It is this partial dopamine agonist effect of aripiprazole 
that has been tested for in reducing cocaine cravings in 
schizophrenic cocaine-dependent subjects (20). It is 
hypothesized that aripiprazole acts either through lowering 
dopamine over-activity, through increasing dopamine 
under-activity, or through some combination of both.
 Aripiprazole has been shown to produce significant 
improvements in positive and negative symptoms in short- 
and long-term studies of patients with schizophrenia or 
schizoaffective disorder (21). Aripiprazole has been shown 
to have a low risk for extrapyramidal symptoms (EPS) and 
hyperprolactinemia, a lack of QTc prolongation, and 
minimal weight gain or sedation (21). Aripiprazole has 
also been found to be useful in treating psychosis associated 
with Parkinson’s Disease (22), preventing relapse in 
bipolar 1 disorder (23), and to be an effective and safe 
adjunctive therapy to standard anti-depressant treatment in 
patients with major depressive disorder (24). The proven 
efficacy and safety of aripiprazole in a number of 
psychiatric disorders provides a rationale for investigating 
this drug in the treatment of methamphetamine induced 
psychosis. The aims of this open-label study were to 
examine the efficacy and tolerability of aripiprazole in the 
treatment of methamphetamine induced psychosis. 
 METHODS
 Subjects
 The study subjects were recruited from the inpatient 
and outpatient clinics of University Malaya Medical 
Centre (UMMC). Eligible subjects included men and 
women aged 18 to 60 years old with a current diagnosis of 
methamphetamine dependence with psychosis. 
Methamphetamine dependence with psychosis was 
defined as (1) meeting the Diagnostic and Statistical 
Manual of Mental Disorders-IV (DSM-IV) diagnosis of 
methamphetamine dependence based on the MINI 
International Neuropsychiatric Interview (MINI) (Sheehan 
et al., 1998b), (2) a score of at least 4 on at least one of the 
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following Positive and Negative Symptoms Scale (PANSS) 
items: P1 - Delusions, P3 - Hallucinatory behaviour, P4 - 
Excitement, P6 - Suspiciousness/persecution, or G9 - 
Unusual thought content, (3) moderate to severe psychosis 
with a score on the Clinical Global Impression Scale - 
Severity of Illness (CGI-S) ≥ 4, (4) duration of psychosis 
for more than 2 weeks, (5) use of methamphetamine at 
least once a week for the past three months at enrollment 
and (6) a positive urine screen for methamphetamine. 
Subjects were also required to be treatment naive and not 
on any psychotrophics, not dependent on other substances 
other than nicotine and not suffering from any current 
intoxification effects of methamphetamine that could 
interfere with the informed consent process or with 
compliance with study procedures. Women of child-
bearing capacity were required to use an appropriate 
method of birth control. 
 Suicidal or homicidal subjects were excluded, along 
with those having serious medical illnesses, known 
hypersensitivity or allergy to aripiprazole, documented 
history of having other mental illness that required 
treatment with antipsychotics, unstable medical conditions 
and females who were positive on a urine pregnancy test 
or lactating.
 Design
 This was a 14-day open-label, prospective study that 
examined the safety and tolerability of aripiprazole for the 
treatment of methamphetamine dependence with 
psychosis. The study ran from September, 2008 through 
December, 2010. 
 Measures
 MINI (25) was used to diagnose methamphetamine 
dependence and the Amphetamine Withdrawal 
Questionnaire (AWQ) (26) was utilized for the evaluation 
of amphetamine withdrawal symptoms. The Brief 
Substance Craving Scale (BSCS) (27) was used to assess 
methamphetamine cravings in 3 dimensions: intensity, 
length, and frequency. The Positive and Negative 
Symptoms Scale (PANSS) (28) was used to measure 
psychotic symptom severity. Extrapyramidal symptoms 
were assessed using the Abnormal Involuntary Movement 
Scale (AIMS) (29) for tardive dyskinesia, the Barnes 
Akathasia Scale (BARS) (30) for drug-induced akathisia 
and the Simpson Angus Scale (SAS) (31) for antipsychotic 
induced Parkinsonism. The Clinical Global Impression 
Scale – Severity of Illness (CGI-S) was used to rate the 
severity of the patient’s illness. Anxiety and depression 
were measured using the Hospital Anxiety Depression 
Scale (HADS) (32). A structured questionnaire was used to 
obtain the patient baseline characteristics, including 
demographic data, history of methamphetamine use and 
past medical and surgical history. 
 Procedures
 The study was approved by the Medical Ethics 
Committee, University Malaya Medical Centre. Informed 
consent was obtained from all subjects prior to performing 
any study procedures. Based on tolerability, oral 
aripiprazole was started at 5-10mg/day once daily for 14 
days. From Day 2 to Day 14, the dose of aripiprazole could 
be adjusted to 5 mg/day, 10 mg/day, or 15 mg/day at the 
investigator’s discretion based on the subject’s clinical 
response and tolerability. The investigator could reduce 
aripiprazole from 10 mg/day to 5 mg/day. Upward titration 
following a dose reduction was allowed during the trial. 
Lorazepam was allowed to be administered to treat 
agitation and anxiety, up to 6 mg/day, but not allowed in 
the morning prior to scheduled assessments. Zolpidem 
tartrate (up 10 mg/day) was permitted to treat sleep 
disturbance throughout the study; all other sleep 
medications were prohibited. Antidepressant (SNRIs/
SSRIs) was also allowed. Anticholinergics were available 
to treat emergent EPS but prophylactic use was not 
permitted. The introduction of other antipsychotic or 
psychoactive drugs during the study was prohibited, and 
these drugs must have been discontinued at least 1 week 
before Day 1. Use of drugs that induce or inhibit hepatic 
cytochrome 3A4 enzymes was also not permitted from 14 
days prior to Day 1 until the end of the treatment period. 
Depot and long-lasting antipsychotics must have been 
stopped within at least two and preferably three dosing 
intervals prior to Day 1 and were prohibited during the 
treatment period. Subjects were evaluated on day 1, 4, 7, 
and 14 with the PANSS, CGI-S, AWQ, BSCA, AIMS, 
BAS and SAS scales. The HADS was conducted only on 
day 1 and 14. Efficacy analyses were based on the 
intention-to-treat (ITT) population.
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 Data Analysis
 Data analysis was carried out by using the Statistical 
Package for the Social Sciences (SPSS, 16.0; SPSS Inc. 
Chicago, III). Descriptive statistics were used to summarize 
demographic variables, past medical and surgical history, 
history of drug use and adverse events. Nominal 
independent variables were described in the form of 
frequencies and percentages. Continuous independent 
variables were summarized and described as means, 
standard deviations, and medians. The paired t-test or 
Wilcoxon signed rank test was used to examine changes in 
the PANSS and its subscales, CGI-S, AWQ, BSCS, BARS, 
SAS, and AIMS scores, by pairing scores at i) baseline 
before initiating aripiprazole and those at day 4, ii) baseline 
before initiating aripiprazole and those at day 7, and iii) 
Figure 1: Disposition of patients  for aripiprazole treatment in methamphetamine induced psychosis
125Klinik Psikofarmakoloji Bülteni, Cilt: 22, Sayı: 2, 2012 / Bulletin of Clinical Psychopharmacology, Vol: 22, N.: 2, 2012 - www.psikofarmakoloji.org
A. H. Sulaiman, J. S. Gill, M. A. Said, M. H. Habil, N. Z. Zainal, N. C. Guan
baseline before initiating aripiprazole and those at day 14. 
The paired t-test using the results of the HADS rating scale 
was conducted between the baseline measurement before 
initiating aripiprazole and that at day 14. 
 RESULTS
 In total, 145 patients were screened but only 49 eligible 
subjects agreed to participate and proceeded to receive the 
study medication. Out of the 49 patients receiving the 
study medication, 8 (16.3%) subjects discontinued early as 
illustrated in Figure 1. Socio-demographic characteristics 
and drug history of the subjects are shown in Table 1. 
Tables 2 and 3 summarize the measurements of the PANSS, 
HADS, BSCS, AWQ, BARS, SAS, and AIMS.
 The mean dose of aripiprazole was 7.0±2.9 mg on day 
1, 7.2±3.3 mg on day 4, 9.2±3.1 mg on day 7 and 9.4±3.6 
mg on day 14. None of the patients received medication 
prior to the study and all were neuroleptic naïve. A total of 
13 (26.5%) patients received concomitant therapies during 
the study. Lorazepam was given to 9 (18.4%) subjects, 4 
for akathisia, 3 for agitation, and 2 for insomnia. Zolpidem 
for insomnia was given to 2 patients (4.1%) and other 2 
patients (4.1%) were given escitalopram for depression.
 Efficacy Measurements
 The primary efficacy measurement was the change 
from baseline in PANSS-Total score to the end of treatment 
(day 14) where baseline was defined as the day the subject 
first received the study medication (day 1). Other primary 
variables included change from baseline in the PANSS 
positive subscales, PANSS negative subscales, PANSS 
general psychopathology subscales, and CGI-S to the end 
of treatment (day 14). The results showed that there was a 
steady decline in the mean PANSS-Total score over the 
course of the study, with a mean reduction of 27.6±21.4 
points (p<0.05, 95% CI (- 34.8, -20.4) from baseline to day 
14 (Table 2), thus indicating a statistically significant 
improvement in patients after receiving aripiprazole. For 
the CGI scale there was also a significant decline with a 
mean reduction of 2.0±1.2 points (p<0.05, 95% CI – 2.4, 
-1.6) from baseline to day 14. Similar statistically 
significant reductions were also seen in all the PANSS 
subscale scores from baseline to day 14. Statistically 
significant improvement was also noted in PANSS-Total, 
all PANSS subscales and CGI-S scores from baseline to 
day 4 and at day 7 (Table 2).
 The secondary efficacy measures were change from 
baseline in the AWQ score, BSCS score and HADS score. 
The results showed that there was a statistically significant 
decline in the mean AWQ score over the course of the 
study, with a mean reduction of -8.5±9.6 points (p<0.05, 
95% CI (-11.8, -5.2) from baseline to day 14 (Table 2). For 
the BSCS scale, the mean reduction was 2.8±3.8 points 
(p<0.05, 95% CI -4.0, -1.5) from baseline to day 14, thus 
indicating a statistically significant improvement in patients 
after receiving aripiprazole. The HADS anxiety subscales 
(Table 2) showed a statistically significant improvement 
with a mean reduction of 3.9±4.8 points (p<0.05, 95% CI 
-5.6, -2.4). Similarly, the HADS depression subscales 
showed a statistically significant improvement with a mean 
Tab le 1: Socio-demographic and drug history of the subjects 
Demographic characteristics N=49
Sex, n (%)
 Male 46 (93.9)
 Female 3 (6.1)
Age, mean years (SD) 34.2 (8.4) 
Race, n (%)
 Malay 30 (61.2)
 Chinese 12 (24.5)
 Indian 7 (14.3)
Marital Status, n (%)
 Married 19 (38.8)
 Single 24 (48.9)
 Divorced 6 (12.3)
Education Level, n (%)
 Tertiary 9 (18.4)
 Secondary 37 (75.5)
 Primary 3(6.1)
Employment Pattern, n (%)
 Full Time Job 38 (77.6)
 Part Time Job 1 (2.0)
 Student 3 (6.1)
 Unemployed 7 (14.3)
Duration of Employment, mean years (SD) 43.6 (51.4)
Income, mean Ringgit Malaysia (SD) 3,310.0 (4,079.3)
Methamphetamine Use History
 Onset Age, mean years (SD) 29.0 (9.0)
 Duration Used, mean years (SD) 5.6 (4.4)
 Amount Used Monthly, mean
     Ringgit Malaysia (SD) 1,386.1 (1,846.8)
Route of Use, n (%)
 Oral 5 (10.2)
 Nasal 14 (28.6)
 Smoking 22 (61.2)
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reduction of 3.5±5.5 points (p<0.05, 95% CI -5.4, -1.7). 
Statistically significant reductions in mean scores were also 
noted for the AWQ and BSCS scales from baseline to day 
4 and to day 7 (Table 2). 
 Safety and Tolerability
 Adverse events (AEs) were reported in 10 (20.4%) 
patients during the 14 day study period (Table 4). Most 
AEs were mild to moderate in intensity. Akathisia was 
rated as moderate in 2 patients and mild in 2 other patients. 
Insomnia was rated as mild in all 4 patients. Agitation was 
rated as mild in all 3 patients. Sedation and depression 
were all rated as moderate. Both akathisia and insomnia 
were judged by the investigator to be associated with the 
study medication. Akathisia did cause 2 patients to 
discontinue from the study. There were no serious adverse 
events during the study period and there were no significant 
changes in BARS, SAS or AIMS scores between baseline 
and days 4, 7, and 14 (Table 4).
Tab le 2: Changes in primary and secondary variables
Variables Baseline Day 4 P value* Day 7 P value* Day 14 P value*
PANSS Total
 Mean (SD) 79.2 (13.7) 71.7±12.3 <0.01 61.7±11.9 <0.01 51.6±14.7 <0.01
 Median (min, max) 79 (62,109) 72 (36,98)  62 (34,85)  52 (30,85)
 
PANSS – P
 Mean (SD) 21.7±5.2 19.0±4.1 0.03 15.7±3.8 <0.01 12.3±4.4 <0.01
 Median (min, max) 21 (12,34) 19 (10,33)  15 (8,24)  12 (7, 22)
PANSS – N
 Mean (SD) 16.8±3.6 15.5±3.6 <0.01 13.5±3.6 <0.01 11.2±3.3 <0.01
 Median (min, max) 16 (10,25) 16 (8, 25)  13 (7, 21)  11 (7, 22)
PANSS – G
 Mean (SD) 40.6±7.2 37.2±6.7 0.02 32.5±6.2 <0.01 27.8±7.7 <0.01
 Median (min, max) 40 (30,60) 37 (18,49)  32 (19, 45)  28 (16, 45)
CGI-S
 Median 4.0 4.0 <0.01# 3.0 <0.01# 1.0 <0.01#
 (interquartile range) (4.0 – 5.0) (4.0 – 4.0)  (2.5 -3.5)  (2.0 – 3.0)
AWQ
 Median 18.0 17.0 0.01# 12.0 <0.01 8.0 <0.01
 (interquartile range) (13.0 – 23.0) (10.0 – 21.0)  (5.0 – 17.0)  (0, 14.5)
BSCS
 Median 8.0 6.0 0.02# 5.0 <0.01# 4 0.01#
 (interquartile range) (2.5 – 9.0) (0 – 9.0)  (0.0 – 7.5)  (0.0 – 6.0) 
HADS – Depression
 Mean (SD) 8.1 (5.0) -  -  4.6 (4.5) <0.01
 Median (min, max) 8 (0,17) -  -  4 (0,16)
HADS – Anxiety 
 Mean (SD) 8.8 (4.9) -  -  3.9 (4.8) <0.01
 Median (min, max) 9 (0,17) -  -  4 (0,16)
 
P<0.001 for all comparisons (day 4, 7 and 14) with baseline, PANSS= Positive and Negative Symptoms Scale
PANSS-P= Positive and Negative Symptoms Scale - Positive subscale, PANSS-N= Positive and Negative Symptoms Scale - Negative subscale
PANSS-G= Positive and Negative Symptoms Scale - General psychopathology subscale, CGI-S= Clinical Global Impression Scale – Severity of Illness
AWQ= Amphetamine Withdrawal Questionnaire, BSCS= Brief Substance Craving Scale, HADS= Hospital Anxiety Depression Scale
*changes from baseline, # Wilcoxon signed rank test
Tab le 3: Treatment emergent adverse events during the study
  All Subjects (N=49)
Study exposure, mean (min, max) days 11.7 (4,14)
Number of patients experienced AE, n (%) 10 (20.4%)
ADVERSE EVENT, n (%) 15 (30.6%)
Akathisia 4 (8.1%)  
Insomnia 4 (8.1%)
Agitation 3 (6.1%)
Sedation 2 (4.1%)
Depression 2 (4.1%)
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 DISCUSSION
 This is the first study in Malaysia to investigate the 
safety and potential efficacy of aripiprazole in treating 
individuals with methamphetamine induced psychosis. 
While the number of patients included in the study was 
small (49 patients), the patients were reasonably 
homogenous in the following: i) all patients had 
methamphetamine induced psychosis, without any history 
of other psychotic disorders, and ii) no patients had prior 
exposure to any antipsychotics (neuroleptic naive). 
However, it should be noted that the subjects in the present 
study do not represent the typical population of 
methamphetamine abusers, including habitual users. Thus, 
the present study has a methodological limitation, where 
only methamphetamine dependent subjects with psychotic 
symptoms were examined. 
 Our subjects exhibited moderate to severe psychotic 
symptoms at baseline. However, following 2 weeks of 
aripiprazole treatment, statistically and clinically 
significant reductions across the assessment instruments 
used in this study were noted. The reduction in symptoms 
was noted as early as day 4, and was sustained until the end 
of the study (day 14). Thus aripiprazole may be a potentially 
effective pharmacological treatment for methamphetamine 
psychosis. We believe that this may be related to the 
efficacy of aripiprazole in treating the positive and negative 
symptoms and depressive and anxiety symptoms. It is not 
clear why aripiprazole may have a positive effect on 
symptoms of depression and anxiety. Agents that have an 
effect on the dopaminergic and serotonergic systems may 
ameliorate symptoms of depression and anxiety (33). The 
effects of aripiprazole may arise from its activity at the 
serotonin 1A (5-HT1A) receptor (34,35), and its partial 
agonist and dopaminergic stabilising qualities (36).
 In our study subjects, treatment with aripiprazole led to 
a significant decline in AWQ and BSCS scores, indicating 
a decrease in the severity of the drug withdrawal syndrome 
and substance cravings. This effect began as early as day 
4, suggesting a rapid onset of action of aripiprazole. This 
finding is in keeping with results from an earlier study (20) 
where aripiprazole significantly alleviated cocaine and 
alcohol cravings in schizophrenia subjects. Therefore, 
aripiprazole might have a beneficial role in addressing 
stimulant withdrawal and cravings.
 In our study, the initial dose of aripiprazole used was 
5-10mg mg/day, and was gradually titrated to higher doses 
of 10 mg/day or 15 mg/day over the study period. The 
doses used in our patient population appeared to be 
effective, as reflected in the significant improvements 
across the efficacy parameters. However, a double-blind 
study by Newton (37) to evaluate the effects of aripiprazole 
treatment on abstinence-related craving and cue-induced 
craving among non-treatment seeking, methamphetamine 
dependent users, reported that aripiprazole given at 15 mg 
is unlikely to be efficacious for the treatment of 
methamphetamine dependence. Whether this discrepancy 
is purely due to different study designs or could be 
attributed to genetic reasons (e.g. different ethnicities need 
different therapeutic doses) remains to be ascertained 
through further research.
 Our study also showed that aripiprazole was well 
tolerated in most patients and safe to be used in 
antipsychotic-naive patients, as shown by the low 
incidence of adverse effects associated with aripiprazole 
and the high retention rate (83.6%) in this study. All the 
AEs were also of mild to moderate severity. The reported 
AEs (akathisia, insomnia, agitation, sedation, and 
depression) were similar to the most common adverse 
events found in other clinical trials of aripiprazole in 
Tab le 4: Changes in safety variables
Variables Baseline Day 4 p value* Day 7 p value* Day 14 p value*
    (95% CI)  (95% CI)  (95% CI)
BARS  
 Mean (SD) 0.7 (0.5) 0.2 (0.8) 0.73 0.3 (1.2) 0.37 0.7 (2.1) 0.16
 Median (min, max) 0 (0, 3) 0 (0, 5) (-0.38, 0.27) 0 (0, 5) (-0.61, 0.23) 0 (0, 8) (-1.1,0.20)
SAS 0 0 - 0 - 0 -
AIMS 0 0 - 0 - 0 -
P > 0.05 for all comparison (day 4, 7 and 14) with baseline, BARS= Barnes Akathisia Scale, SAS= Simpson Angus Scale, AIMS= Abnormal Involuntary Movement Scale
*changes from baseline using Wilcoxon signed rank test
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schizophrenia (38,39). There was a non-significant 
increase in BARS, mainly due to four patients who 
reported akathisia. Akathisia is not uncommon with 
aripiprazole. While second-generation antipsychotic 
drugs have been reported to cause a lower incidence of 
extrapyramidal symptoms (EPSs) than typical 
antipsychotic drugs, AEs such as akathisia have been 
observed with atypical antipsychotic drugs (39,40). 
 Currently, the data on efficacy of antipsychotics in 
methamphetamine induced psychosis are still limited. 
Only a single small randomised controlled trial (41) 
involving 58 participants has been published. That study 
compared the efficacy and tolerability of two antipsychotic 
drugs, olanzapine and haloperidol, in treating amphetamine-
induced psychosis, where both drugs were found to be 
efficacious. Whether the limited evidence from our current 
study using aripiprazole can be applied to all 
methamphetamine dependent psychotic patients in 
Malaysia is still not known, as the treatment of 
methamphetamine induced psychosis with aripiprazole 
needs to be further investigated in larger randomised 
controlled samples. Further studies of methamphetamine 
induced psychotic symptoms and the prevalence of relapse 
of psychosis in the presence of methamphetamine are also 
crucial to develop study designs appropriate for treatment 
studies of methamphetamine psychosis.
 The limitations of this study were the small sample 
size, the open-label design, and the absence of a placebo 
arm. We attempted to minimize the limitations of the open-
label design by including self-rated scales in addition to 
the observer-rated scales. In this study, we noted that 
subjects experienced improvement based on both types of 
efficacy measurements. Without a placebo arm, the effect 
of aripiprazole cannot be reliably distinguished from self-
abatement after stopping methamphetamines. However, it 
is worth noting that subjects in this study responded 
rapidly, as early as day 4. We assume this rapid response 
could be due to aripiprazole rather than a natural self-
limiting response. 
 CONCLUSIONS
 This 2-week, open-label study shows that aripiprazole 
given once-daily at 10 mg/day to 15 mg/day improved the 
psychotic symptoms associated with methamphetamine 
use, as measured with PANSS scores. In addition, the 
treatment also improved depressive and anxiety symptoms, 
as well as reduced drug withdrawal symptoms and 
substance craving severity. The treatment was generally 
well tolerated with mild to moderate AEs comparable to 
other aripiprazole studies. Aripiprazole may be a potential 
treatment option for methamphetamine induced psychosis, 
but its efficacy needs to be confirmed by randomised, 
larger, and longer-duration studies.
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